STOCK FOCUS OF THE DAY
Gamuda : Robust prospects beyond KVMRT
BUY
We maintain BUY on Gamuda with a higher fair value of
RM5.40/share (previously: RM5.25/share) as we roll-forward our valuation base
to FY15F. Our fair value upgrade also takes into account the acquisition of a
further 20% stake in KESAS from PNB (completed in June).
Core FY14 net profit rose 9% YoY on higher construction and
property earnings. Excluding the impact from FRS11, core construction earnings
rose 6% YoY although margins were a tad lower at 8.7% in FY14 (FY13: 9.9%). The
MMC-Gamuda JV continues to deliver for the KVMRT line 1; work progress has
reached 52% and 35% for the tunneling and PDP components, respectively. The
entire tunneling works should be completed by the second quarter of next year,
while system handover for the elevated portion should commence in a months’
time.
We understand that the roll-out for KVMRT2 has been set back
by a couple of months following an additional review of the line by a
government-appointed consultant. But, management maintained its view that the
new line could be formalised by year-end with major awards to come out by
mid-2016 onwards (tenders: late-2015). On the other hand, core property
earnings surged 19% YoY largely on the strong pre-sales trajectory over the
last two FYs and stable margins (unbilled sales: RM1.7bil). New property sales
slipped 55% YoY to RM300mil in 4Q. Reflecting its cautious outlook for FY15,
management has revised downwards its FY15F sales target by 8% to RM1.8bil.
Remain invested in Gamuda. More landbanking moves are
possible within a year; ~RM1.3bil has been set aside in search of more land,
including those in Penang. Gamuda’s track record as the PDP for KVMRT1 also
puts it in good stead to bid for a similar role under the Penang government’s
transport master plan. The PDP contract could be awarded by mid-2015.
Others :
Public Bank : Scaling back our earnings expectations
HOLD
NEWS HIGHLIGHTS
DiGi.Com : In talks with Thai mobile app developer
Malaysian Airline System : MAS Act to be tabled in next
parliament session
IHH Healthcare : “Higher health spending in Asia”
DISCLAIMER:
The information and opinions in this report were prepared by
AmResearch Sdn Bhd. The investments discussed or recommended in this report may
not be suitable for all investors. This report has been prepared for
information purposes only and is not an offer to sell or a solicitation to buy
any securities. The directors and employees of AmResearch Sdn Bhd may from time
to time have a position in or with the securities mentioned herein. Members of
the AmInvestment Group and their affiliates may provide services to any company
and affiliates of such companies whose securities are mentioned herein. The
information herein was obtained or derived from sources that we believe are
reliable, but while all reasonable care has been taken to ensure that stated
facts are accurate and opinions fair and reasonable, we do not represent that
it is accurate or complete and it should not be relied upon as such. No
liability can be accepted for any loss that may arise from the use of this
report. All opinions and estimates included in this report constitute our
judgement as of this date and are subject to change without notice.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.